Brit J Cancer: Relationship between metformin and survival rates in lung cancer patients

In a recent study published in British Journal of Cancer, an authoritative journal in the field of oncology, researchers aimed to assess the link between metformin use and survival in lung cancer (LC) patients nationwide in Norway.
the study linked the Norwegian prescription database to 22,324 patients diagnosed with LC in the Norwegian Cancer Registry between 2005 and 2014.
researchers used multivariate time fixation and time-dependent Cox regression to estimate the association between the use of metformin before and after diagnosis and the overall survival of patients (OS) and LCSS.
metformin before diagnosis was not associated with improved survival in all patients.
this, in patients with squamous cell carcinoma (SCC) (risk ratio (HR) of 0.79; 95% of patients with a confidence interval (CI) of 0.62-0.99) and regional SCC patients (HR of 0.67; 95% CI of 0.47-0.95), metformin was used before diagnosis to be associated with better LCSS.
use of metformin after diagnosis and in all patients (HR=0.83; 95% CI is 0.73-0.95), SCC patients (HR=0.75; 95% CI is 0.57-0.98), regional LC (HR=0.74; 95% CI is 0.59-0.94) and regional SCC (HR is 0.57; 95% CI is 0.38-0.86) LCSS improvement related.
OS got similar results.
cumulative use of patients found a dose response relationship between all patients, adenocarcinoma and SCC patients, as well as regional and metastatic LC patients.
can be seen that the use of metformin can improve the survival rate of LC patients, especially regional SCC patients LCSS.
further prospective studies are needed to clarify the role of metformin in LC therapy.
。